-
公开(公告)号:US20120231005A1
公开(公告)日:2012-09-13
申请号:US13503726
申请日:2010-10-29
申请人: Peter Peizhi Luo , Kevin Caili Wang , Pingyu Zhong , Mark Hsieh , Yan Li , Xinwei Wang , Feng Dong , Andrei Golosov , Yan Ni , Weirong Wang , Laurence B. Peterson , Rose Cubbon
发明人: Peter Peizhi Luo , Kevin Caili Wang , Pingyu Zhong , Mark Hsieh , Yan Li , Xinwei Wang , Feng Dong , Andrei Golosov , Yan Ni , Weirong Wang , Laurence B. Peterson , Rose Cubbon
IPC分类号: C07K16/40 , C12N9/99 , C12N1/21 , C12N15/13 , C12N5/10 , C12P21/02 , A61K39/395 , C12N15/63 , C12N1/19
CPC分类号: C07K16/40 , C07K2317/21 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
摘要翻译: 公开了人前体蛋白转化酶枯草杆菌蛋白酶-Kexin 9型(“PCSK9”)的拮抗剂。 所公开的拮抗剂在抑制PCSK9功能方面是有效的,因此,呈现用于治疗与PCSK9活性相关的病症的所需拮抗剂。 本发明还公开了编码所述拮抗剂,载体,宿主细胞和包含拮抗剂的组合物的核酸。 还公开了制备PCSK9特异性拮抗剂的方法以及使用拮抗剂抑制或拮抗PCSK9功能的方法,并形成了本公开的重要的附加方面。
-
公开(公告)号:US20110124528A1
公开(公告)日:2011-05-26
申请号:US12916077
申请日:2010-10-29
申请人: Peizhi Luo , Mark Hsieh , Pingyu Zhong , Caili Wang , Yicheng Cao , Shengjiang Liu
发明人: Peizhi Luo , Mark Hsieh , Pingyu Zhong , Caili Wang , Yicheng Cao , Shengjiang Liu
IPC分类号: C40B50/02
CPC分类号: C07K16/22 , B01J2219/00689 , B01J2219/00695 , B01J2219/007 , B01J2219/00725 , C07K16/00 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C40B40/10 , G16B35/00 , G16C20/60
摘要: The present invention provides a methodology for efficiently generating and screening protein libraries for optimized proteins with desirable biological functions, such as improved binding affinity towards biologically and/or therapeutically important target molecules. The process is carried out computationally in a high throughput manner by mining the ever-expanding databases of protein sequences of all organisms, especially human. In one embodiment, a method for constructing a library of designed proteins, comprising the steps of: providing an amino acid sequence derived from a lead protein, the amino acid sequence being designated as a lead sequence; comparing the lead sequence with a plurality of tester protein sequences; and selecting from the plurality of tester protein sequences at least two peptide segments that have at least 15% sequence identity with the lead sequence, the selected peptide segments forming a hit library; and forming a library of designed proteins by substituting the lead sequence with the hit library. The library of designed proteins can be expressed in vitro or in vivo to produce a library of recombinant proteins that can be screened for novel or improved function(s) over the lead protein, such as an antibody against therapeutically important target.
摘要翻译: 本发明提供了一种用于有效地产生和筛选具有所需生物学功能的优化蛋白质的蛋白质文库的方法,例如改善对生物和/或治疗重要的靶分子的结合亲和力。 该过程以高通量方式通过开发不断扩大的所有生物体,特别是人的蛋白质序列数据库进行。 在一个实施方案中,构建设计蛋白质文库的方法,包括以下步骤:提供衍生自铅蛋白的氨基酸序列,所述氨基酸序列指定为引导序列; 将引导序列与多个测试蛋白序列进行比较; 以及从所述多个测试蛋白序列中选择与所述引物序列具有至少15%序列同一性的至少两个肽片段,所选择的肽片段形成命中文库; 并通过用命中库替换引导序列形成设计蛋白质的文库。 设计的蛋白质文库可以在体外或体内表达,以产生重组蛋白文库,该文库可以筛选出超过铅蛋白质的新的或改进的功能,例如针对治疗重要靶标的抗体。
-
公开(公告)号:US20050148001A1
公开(公告)日:2005-07-07
申请号:US10996191
申请日:2004-11-22
申请人: Peizhi Luo , Mark Hsieh
发明人: Peizhi Luo , Mark Hsieh
IPC分类号: C07K16/00 , C40B40/10 , C40B50/02 , C12Q1/68 , G01N33/53 , G06F19/00 , G01N33/48 , G01N33/50 , C07H21/04
CPC分类号: C40B40/10 , B01J2219/00689 , B01J2219/00695 , B01J2219/007 , B01J2219/00725 , C07K16/00 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/622 , C07K2319/00 , C12N15/1089 , G16B35/00 , G16C20/60
摘要: Methods and systems are provided for constructing recombinant antibody libraries based on three-dimensional structures of antibodies from various species including human. In one aspect, a library of antibodies with diverse sequences is efficiently constructed in silico to represent the structural repertoire of the vertebrate antibodies. Such a functionally representative library provides a structurally diverse and yet functionally more relevant source of antibody candidates which can then be screened for high affinity binding to a wide variety of target molecules, including but not limited to biomacromolecules such as protein, peptide, and nucleic acids, and small molecules.
摘要翻译: 提供了基于来自包括人在内的各种物种的抗体的三维结构构建重组抗体文库的方法和系统。 在一个方面,具有不同序列的抗体文库有效地构建成计算机,以表示脊椎动物抗体的结构谱。 这样的功能代表性的文库提供了结构上多样但功能上更相关的抗体候选来源,然后可以筛选其与多种靶分子的高亲和力结合,包括但不限于生物大分子如蛋白质,肽和核酸 ,和小分子。
-
公开(公告)号:US20200377608A1
公开(公告)日:2020-12-03
申请号:US16768500
申请日:2018-11-30
申请人: Peter Peizhi LUO , Adagene Inc.
发明人: Peter Peizhi LUO , Guizhong LIU , Fangyong DU
摘要: Provided herein are methods relating to the use of CD137 Ligand (CD137L) expression; methods relating to the use of CD137L expression as a biomarker; and methods for predicting, assessing, and/or aiding in assessment of responsiveness of a subject in need thereof to treatment with particular anti-cancer therapies (e.g., an anti-CD137 antibody, a checkpoint blockade immunotherapy).
-
公开(公告)号:US08802827B2
公开(公告)日:2014-08-12
申请号:US13503726
申请日:2010-10-29
申请人: Peter Peizhi Luo , Kevin Caili Wang , Pingyu Zhong , Mark Hsieh , Yan Li , Xinwei Wang , Feng Dong , Andrei Golosov , Yan Ni , Weirong Wang , Laurence B. Peterson , Rose Cubbon
发明人: Peter Peizhi Luo , Kevin Caili Wang , Pingyu Zhong , Mark Hsieh , Yan Li , Xinwei Wang , Feng Dong , Andrei Golosov , Yan Ni , Weirong Wang , Laurence B. Peterson , Rose Cubbon
IPC分类号: C07K16/40 , C07K16/00 , A61K39/395
CPC分类号: C07K16/40 , C07K2317/21 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
摘要翻译: 公开了人前体蛋白转化酶枯草杆菌蛋白酶-Kexin 9型(“PCSK9”)的拮抗剂。 所公开的拮抗剂在抑制PCSK9功能方面是有效的,因此,呈现用于治疗与PCSK9活性相关的病症的所需拮抗剂。 本发明还公开了编码所述拮抗剂,载体,宿主细胞和包含拮抗剂的组合物的核酸。 还公开了制备PCSK9特异性拮抗剂的方法以及使用拮抗剂抑制或拮抗PCSK9功能的方法,并形成了本公开的重要的附加方面。
-
6.
公开(公告)号:US20120129702A1
公开(公告)日:2012-05-24
申请号:US12914105
申请日:2010-10-28
申请人: Peizhi Luo , Mark Hsieh , Pingyu Zhong , Caili Wang
发明人: Peizhi Luo , Mark Hsieh , Pingyu Zhong , Caili Wang
IPC分类号: C40B10/00
CPC分类号: C07K16/00 , B01J2219/00689 , B01J2219/00695 , B01J2219/007 , B01J2219/00725 , C07K16/005 , C07K16/22 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2319/00 , C12N15/1089 , C40B40/10 , G16B35/00 , G16C20/60
摘要: The present invention provides a structure-based methodology for efficiently generating and screening a library of recombinant antibodies for optimized antibodies with desirable functions, such as higher binding affinity or low immunogenicity. In one embodiment, a method is provided for constructing a library of antibody sequences based on a three dimensional structure of a lead antibody. The method comprises: providing a lead structural template comprising the amino acid sequence of the variable region of the heavy chain (VH) or light chain (VL) of a lead antibody, comparing the lead template sequence with a plurality of tester protein sequences; selecting a hit library from the tester protein sequences; determining if a member of the hit library is structurally compatible with the lead structural template using a scoring function; selecting members for the hit library that score equal to or better than the lead sequence and screening members for improved function(s).
摘要翻译: 本发明提供了一种基于结构的方法,用于有效地产生和筛选重组抗体文库,以获得具有所需功能的优化抗体,例如较高的结合亲和力或低免疫原性。 在一个实施方案中,提供了一种基于铅抗体的三维结构构建抗体序列文库的方法。 该方法包括:提供包含铅抗体的重链(VH)或轻链(VL)的可变区的氨基酸序列的引导结构模板,将引导模板序列与多个测试蛋白序列进行比较; 从测试蛋白序列中选择一个命中库; 确定命中库的成员是否使用得分函数在结构上与引导结构模板兼容; 选择得分等于或优于前导序列的命中库的成员,并筛选成员以改进功能。
-
公开(公告)号:US08030469B2
公开(公告)日:2011-10-04
申请号:US12263919
申请日:2008-11-03
申请人: Teikichi Aoyagi , Peter Peizhi Luo , Pingyu Zhong , Mark Hsieh , Yan Li , Kevin Caili Wang , Chikao Morimoto
发明人: Teikichi Aoyagi , Peter Peizhi Luo , Pingyu Zhong , Mark Hsieh , Yan Li , Kevin Caili Wang , Chikao Morimoto
IPC分类号: C07H21/02 , C07H21/04 , A61K39/395 , A61K39/00
CPC分类号: C07K16/2896 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92 , G01N33/574 , G01N2333/70596 , G01N2500/00 , Y02A50/473
摘要: The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.
摘要翻译: 本发明提供新的抗CD26抗体和其它相关多肽,以及编码抗体和多肽的新型多核苷酸。 本发明还提供了制备抗体和多肽的方法。 进一步提供包含抗体或多肽的组合物和细胞。 还提供了使用抗体和/或多肽的方法,例如抑制细胞增殖和治疗与CD26相关的病症。
-
公开(公告)号:US07462698B2
公开(公告)日:2008-12-09
申请号:US11492498
申请日:2006-07-24
申请人: Teikichi Aoyagi , Peter Peizhi Luo , Pingyu Zhong , Mark Hsieh , Yan Li , Kevin Caili Wang , Chikao Morimoto
发明人: Teikichi Aoyagi , Peter Peizhi Luo , Pingyu Zhong , Mark Hsieh , Yan Li , Kevin Caili Wang , Chikao Morimoto
IPC分类号: C12P21/08 , C07K16/00 , A61K35/395 , A61K39/00
CPC分类号: C07K16/2896 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92 , G01N33/574 , G01N2333/70596 , G01N2500/00 , Y02A50/473
摘要: The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.
摘要翻译: 本发明提供新的抗CD26抗体和其它相关多肽,以及编码抗体和多肽的新型多核苷酸。 本发明还提供了制备抗体和多肽的方法。 进一步提供包含抗体或多肽的组合物和细胞。 还提供了使用抗体和/或多肽的方法,例如抑制细胞增殖和治疗与CD26相关的病症。
-
9.
公开(公告)号:US07117096B2
公开(公告)日:2006-10-03
申请号:US10153159
申请日:2002-05-20
申请人: Peizhi Luo , Mark Hsieh , Pingyu Zhong , Caili Wang
发明人: Peizhi Luo , Mark Hsieh , Pingyu Zhong , Caili Wang
CPC分类号: C07K16/00 , B01J2219/00689 , B01J2219/00695 , B01J2219/007 , B01J2219/00725 , C07K16/005 , C07K16/22 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2319/00 , C12N15/1089 , C40B40/10 , C40B50/02
摘要: The present invention provides a structure-based methodology for efficiently generating and screening protein libraries for optimized proteins with desirable biological functions, such as antibodies with high binding affinity and low immunogenicity in humans. In one embodiment, a method is provided for constructing a library of antibody sequences based on a three dimensional structure of a lead antibody. The method comprises: providing an amino acid sequence of the variable region of the heavy chain (VH) or light chain (VL) of a lead antibody, the lead antibody having a known three dimensional structure which is defined as a lead structural template; identifying the amino acid sequences in the CDRs of the lead antibody; selecting one of the CDRs in the VH or VL region of the lead antibody; providing an amino acid sequence that comprises at least 3 consecutive amino acid residues in the selected CDR, the selected amino acid sequence being a lead sequence; comparing the lead sequence profile with a plurality of tester protein sequences; selecting from the plurality of tester protein sequences at least two peptide segments that have at least 10% sequence identity with lead sequence, the selected peptide segments forming a hit library; determining if a member of the hit library is structurally compatible with the lead structural template using a scoring function; and selecting the members of the hit library that score equal to or better than or equal to the lead sequence. The selected members of the hit library can be expressed in vitro or in vivo to produce a library of recombinant antibodies that can be screened for novel or improved function(s) over the lead antibody.
摘要翻译: 本发明提供了一种基于结构的方法,用于有效地产生和筛选具有所需生物学功能的优化蛋白质的蛋白质文库,例如人类具有高结合亲和力和低免疫原性的抗体。 在一个实施方案中,提供了一种基于铅抗体的三维结构构建抗体序列文库的方法。 该方法包括:提供铅抗体的重链(V H H H H)或轻链(V L L L)的可变区的氨基酸序列,所述引物抗体 具有已知的三维结构,其被定义为引导结构模板; 识别引导抗体的CDR中的氨基酸序列; 选择引导抗体的V H H或V L L区域中的一个CDR; 提供在所选择的CDR中包含至少3个连续氨基酸残基的氨基酸序列,所选择的氨基酸序列是引导序列; 将引导序列谱与多个测试蛋白序列进行比较; 从多个测试蛋白序列中选择与引导序列具有至少10%序列同一性的至少两个肽段,所选择的肽段形成命中文库; 确定命中库的成员是否使用得分函数在结构上与引导结构模板兼容; 并且选择得分等于或者好于或等于前导序列的命中库的成员。 命中文库的所选成员可以在体外或体内表达以产生重组抗体文库,其可以筛选出超过该抗体的新的或改进的功能。
-
公开(公告)号:US20200248336A1
公开(公告)日:2020-08-06
申请号:US16640679
申请日:2017-08-21
申请人: Peter Peizhi LUO , Adagene Inc.
发明人: Peter Peizhi LUO , Yan LI , Fangyong DU
摘要: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.
-
-
-
-
-
-
-
-
-